Helleberg, Marie ; Jørgensen, Karin Meinike ; Hare, Rasmus Krøger ; Datcu, Raluca ; Chowdhary, Anuradha ; Arendrup, Maiken Cavling (2020) Rezafungin In Vitro Activity against Contemporary Nordic Clinical Candida Isolates and Candida auris Determined by the EUCAST Reference Method Antimicrobial Agents and Chemotherapy, 64 (4). ISSN 0066-4804
Full text not available from this repository.
Official URL: http://doi.org/10.1128/AAC.02438-19
Related URL: http://dx.doi.org/10.1128/AAC.02438-19
Abstract
Rezafungin (formerly CD101) is a novel echinocandin in clinical development. EUCAST epidemiological cutoff values (ECOFFs) have not yet been established. We determined the in vitro activity of rezafungin and comparators against 1,293 Nordic yeast isolates and 122 Indian Candida auris isolates and established single-center wild-type upper limits (WT-UL). The isolates (19 Candida spp. and 13 other yeast species) were identified using Chromagar; matrix-assisted laser desorption ionization–time of flight (MALDI-TOF); and, when needed, internal transcribed spacer sequencing. EUCAST E.Def 7.3.1 susceptibility testing included rezafungin, anidulafungin, micafungin, amphotericin B, and fluconazole. WT-UL were established following EUCAST principles for visual and statistical ECOFF setting. fks target genes were sequenced for rezafungin non-wild-type isolates. EUCAST clinical breakpoints for fungi version 9.0 were adopted for susceptibility classification. Rezafungin had species-specific activity similar to that of anidulafungin and micafungin. On a milligram-per-liter basis, rezafungin was overall less active than anidulafungin and micafungin but equally or more active than fluconazole and amphotericin B against the most common Candida species, except C. parapsilosis. We identified 37 (3.1%) rezafungin non-wild-type isolates of C. albicans (1.9%), C. glabrata (3.0%), C. tropicalis (2.7%), C. dubliniensis (2.9%), C. krusei (1.2%), and C. auris (14.8%). Alterations in Fks hot spots were found in 26/26 Nordic and 8/18 non-wild-type C. auris isolates. Rezafungin displayed broad in vitro activity against Candida spp., including C. auris. Adopting WT-UL established here, few Nordic strains, but a significant proportion of C. auris isolates, had elevated MICs with mutations in fks target genes that conferred echinocandin cross-resistance. fks1 mutations raised rezafungin MICs notably less than anidulafungin and micafungin MICs in C. auris.
Item Type: | Article |
---|---|
Source: | Copyright of this article belongs to American Society for Microbiology. |
Keywords: | Rezafungin; In Vitro Activity; MIC; Candida; Candida auris; EUCAST Antifungal Resistance; Antifungal Susceptibility Testing; Echinocandin. |
ID Code: | 117301 |
Deposited On: | 19 Apr 2021 06:18 |
Last Modified: | 19 Apr 2021 06:18 |
Repository Staff Only: item control page